Clinical Trials Directory

Trials / Terminated

TerminatedNCT00821717

EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure

A Randomised, Controlled, Observer-blinded Phase III Clinical Trial to Compare the Effect of Intravenous Ferric Carboxymaltose to Placebo on Exercise Capacity and Cardiac Function in Patients With Chronic Heart Failure and Iron Deficiency

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
35 (actual)
Sponsor
Vifor Pharma · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study is designed to assess, relative to placebo, the effects on the evolution of exercise capacity and symptomatic status of the addition of iron treatment with FCM (ferric carboxymaltose) to the basic regimen of ambulatory patients with stable symptomatic chronic CHF (congestive heart failure) and iron deficiency.

Conditions

Interventions

TypeNameDescription
DRUGFerinject ® (Ferric carboxymaltose)Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit. After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase).
DRUGNormal saline (0.9%)During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.

Timeline

Start date
2008-12-01
Primary completion
2009-10-01
Completion
2011-01-01
First posted
2009-01-13
Last updated
2015-06-03

Locations

41 sites across 5 countries: Denmark, France, Germany, Israel, Netherlands

Source: ClinicalTrials.gov record NCT00821717. Inclusion in this directory is not an endorsement.